Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis.
Adolescents
COVID-19
Children
Immunization
Immunosuppressed
Systematic review
Vaccination
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
25
01
2022
revised:
29
05
2022
accepted:
01
06
2022
pubmed:
19
6
2022
medline:
8
7
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% - 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 - 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine.
Identifiants
pubmed: 35716417
pii: S1386-6532(22)00129-9
doi: 10.1016/j.jcv.2022.105196
pmc: PMC9162782
pii:
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105196Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Références
J Chin Med Assoc. 2020 Jun;83(6):527-533
pubmed: 32502117
Vaccines (Basel). 2021 Aug 04;9(8):
pubmed: 34451982
Arch Dis Child. 2022 Mar;107(3):e16
pubmed: 34740880
JAMA. 2021 Nov 23;326(20):2002
pubmed: 34812857
Pediatr Rep. 2021 Sep 01;13(3):530-533
pubmed: 34564344
Eur J Cancer. 2021 Sep;154:30-34
pubmed: 34233234
J Pediatr Nurs. 2021 Mar-Apr;57:96-98
pubmed: 33342640
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Front Immunol. 2021 Oct 04;12:727850
pubmed: 34671350
BMJ. 2021 May 13;373:n1197
pubmed: 33985969
Pediatr Blood Cancer. 2021 Nov;68(11):e29295
pubmed: 34398511
Pediatr Infect Dis J. 2021 Jul 1;40(7):e281-e283
pubmed: 34097667
N Engl J Med. 2021 Jul 15;385(3):239-250
pubmed: 34043894
Gut. 2022 Sep;71(9):1922-1924
pubmed: 34815272
Transplantation. 2021 Nov 1;105(11):e226-e233
pubmed: 34381004
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
J Pediatr. 2021 Nov;238:26-32.e1
pubmed: 34339728
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864
pubmed: 34427638
Ann Intern Med. 2021 Oct;174(10):1404-1408
pubmed: 34280332
Emerg Infect Dis. 2021 Nov;27(11):2919-2922
pubmed: 34570694
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
J R Soc Med. 2021 Nov;114(11):513-524
pubmed: 34723680
MMWR Morb Mortal Wkly Rep. 2021 Oct 22;70(42):1483-1488
pubmed: 34673751
BMJ. 2021 Aug 20;374:n2052
pubmed: 34417166
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Inflamm Bowel Dis. 2022 Jul 1;28(7):1019-1026
pubmed: 34528661
Pediatr Clin North Am. 2021 Oct;68(5):961-976
pubmed: 34538306
World J Pediatr. 2021 Oct;17(5):458-461
pubmed: 34586608
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Vaccine. 2021 Sep 7;39(38):5333-5336
pubmed: 34393021
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Circulation. 2021 Aug 10;144(6):471-484
pubmed: 34281357
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Am J Surg. 2015 Apr;209(4):623-6
pubmed: 25698077
JAMA. 2021 Oct 12;326(14):1365
pubmed: 34636874
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
AAPS PharmSciTech. 2021 Jun 7;22(5):172
pubmed: 34100150
Emerg Microbes Infect. 2021 Dec;10(1):1589-1597
pubmed: 34197281
J Infect Dis. 2021 Aug 2;224(3):431-434
pubmed: 34007998
Hong Kong Med J. 2021 Feb;27(1):35-45
pubmed: 32994372
Children (Basel). 2021 Jul 18;8(7):
pubmed: 34356586
Lancet Infect Dis. 2021 Jul;21(7):950-961
pubmed: 33705727
Vaccines (Basel). 2021 Nov 09;9(11):
pubmed: 34835228
Am J Transplant. 2022 Feb;22(2):669-672
pubmed: 34517430
Int J Infect Dis. 2020 Sep;98:14-15
pubmed: 32585285
N Engl J Med. 2021 Dec 9;385(24):2241-2251
pubmed: 34379915
Nat Med. 2021 Jun;27(6):1071-1078
pubmed: 34007070
Pediatr Blood Cancer. 2021 Dec;68(12):e29397
pubmed: 34636133
Lancet Infect Dis. 2021 Dec;21(12):1645-1653
pubmed: 34197764
Arch Dis Child. 2022 Feb;107(2):205-207
pubmed: 34446440
Lancet Infect Dis. 2022 Feb;22(2):196-208
pubmed: 34536349
Front Pediatr. 2021 Aug 23;9:721257
pubmed: 34497784
J Am Acad Child Adolesc Psychiatry. 2021 Nov;60(11):1332-1334
pubmed: 34481918
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Clin Infect Dis. 2022 Aug 24;75(1):e783-e791
pubmed: 34551104
J Med Virol. 2021 Dec;93(12):6588-6594
pubmed: 34270094
Pediatr Nephrol. 2022 Feb;37(2):449-453
pubmed: 34522992
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1294-1299
pubmed: 34529636
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428